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Abstract
Familial hypercholesterolaemia (FH) is a relatively common genetic disorder associated with high risk of coronary
heart disease that is preventable by early diagnosis and treatment. In a previous article, we reviewed the evidence
for clinical management, models of care and health economic evaluations. The present commentary emphasises that
collective action is needed to strengthen our approaches to evidence-based care, including better diagnosis and
access to effective therapies. We detail how contemporary innovations in inter-operable, web-based, open-source
and secure registries can provide the supporting infrastructure to: (i) address a current gap in the flow of data for
measuring the quality of healthcare; (ii) support basic research through provision of high-quality, de-identified
aggregate data; (iii) enable equitable access to clinical trials; and (iv) support efforts to disseminate evidence for best
practice and information for care services. We describe how these aspects of enabling infrastructure will be
incorporated into the development of a National FH Registry for Australasia, and proffer that a coordinated response
to FH would be enhanced through a global network of inter-operable registries.
Keywords: disease registry, familial hypercholesterolaemia, health economic evaluations, model of care,
open-source, web-based.
Definition/impact
Familial hypercholesterolaemia (FH) is a disorder that causes
severe elevation in plasma cholesterol and a high risk of
premature coronary artery disease. Heterozygous FH (heFH)
occurs in approximately 1 in 500 people, affects all race/
ethnic groups, and leads to a greater than 50% chance of
coronary heart disease by the age of 50 years in men and at
least 30% in women by the age of 60 years. Homozygous FH
(hoFH) occurs in approximately 1 in a million individuals,
and is characterised by greater disease severity, with early
death from coronary heart disease.1
Demographics
Our knowledge of the geographical distribution and epide-
miology of hoFH and heFH is largely incomplete. Founder
populations, or those with higher levels of consanguinity,
exhibit a high prevalence of the condition.1 The quality and
coverage of data necessary for optimally designing health
systems to cater for specific sectors of society are, however,
not yet available. The need for more epidemiological evi-
dence is particularly high in countries such as Australia,
where the urban and rural healthcare systems differ and
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where the geographical distribution of FH-carrying family
pedigrees is yet to be mapped.
Diagnosis
Early interventions can reduce the incidence of coronary
artery disease in FH.2 In Australia, less than 20% of cases of
FH have been identified and those diagnosed remain inad-
equately treated.3 The use of cascade screening has proven
effective,4 but is yet to be consistently and nationally coor-
dinated and supported.5 A systematic approach to collecting
health economic and clinical data from existing cascade
screening and awareness programmes would enhance the
planning, coordination and support for both current and
future services.3
Genetic typing
The genetic basis of FH has been mapped to more than 1700
mutations, where low-density lipoprotein (LDL) receptor
function ranges from completely absent to approximately
25% of normal receptor activity.6–8 Mutations in ApoB and
proprotein convertase subtilisin/kexin type 9 (PCSK9) are
less frequent causes of autosomal dominant hypercholes-
terolaemia. Diagnostic laboratories typically undertake
DNA testing in the absence of coordinated, integrated
information-based registries. Registry reporting of genetic
typing would ensure access to an overview of genetic data
and contribute to overarching efforts of clinical networks to
develop and promulgate best practice.
Therapy
Clinical management predominately involves early prescrip-
tion of statin therapies with or without ezetimibe to lower the
plasma LDL-C level.9 However, in FH even high-potency
statins with other agents do not allow attainment of recom-
mended treatment targets for plasma LDL-C concentration.
Statins can also have dose-dependent side effects, most
notably skeletal muscle symptoms. Currently, other therapeu-
tics for FH comprise fibrates and bile acid sequestrants
(resins).9 An MTP inhibitor (lomitapide/Juxtapid, Aegerion
Pharmaceuticals, Cambridge, MA, USA) and an oligonucle-
otide developed against Apo-B 100 mRNA (mipomersen) are
also approved for hoFH.10 Mipomersen (marketed as
Kynamro by Genzyme, Cambridge, MA, USA) is the first
systemic oligonucleotide inhibitor to reach the market for
hoFH.11 The safety and effectiveness of Kynamro and Juxtapid
have not been established in patients with hypercholestero-
laemia who do not have hoFH, and the effects of these two
drugs on cardiovascular morbidity and mortality has not been
determined. The development of other classes of therapeutic
drugs (monoclonal antibodies and anti-sense oligonucle-
otides, small interfering RNAs, and inhibitory adnectins) that
target the inhibition of PCSK9 is also under development and
may become available. Overall, the efficacy and safety of most
of these novel therapies have not been tested and clinical
trials are needed. The pathways in healthcare that enable
clinical trials for FH are poorly defined, necessitating better
engagement and coordinated actions between relevant
stakeholders.
Registry objectives
In a previous article, we reviewed the evidence supporting
the treatment, models of care and health economics of FH.12
Registries can enhance the healthcare of FH and other
conditions,13–17 particularly where there are evidence gaps
for informing improvements. The World Health Organization
definition of ‘patient registry’ is ‘a file of documents contain-
ing uniform information about individual persons, collected
in a systematic and comprehensive way, in order to serve a
pre-determined scientific, clinical or policy purpose’.18 In the
case of an FH registry, the population should include both
affected and unaffected relatives of the index case so that
the impact of cascade screening programmes can be cap-
tured, and to enable recruitment of cases and controls for
observational studies.
Patient registries can be key instruments for clinical
research and improving healthcare planning and patient
care. The Simon Broome Register is an observational cohort
that has been in operation in Britain since 1980 and has
recruited, from 21 lipid clinics, over 3382 individuals with
heFH. The outputs from this registry have allowed analyses
of the natural history, evidence for treatment and provided
data for health economic evaluations.19–23 The registry of the
Medical Genetics Laboratory at Oslo University Hospital con-
tains more than 4400 patients with a molecular genetic
diagnosis of FH, and has been successfully used to examine
pregnancy outcomes.24
Recognition of the need to improve outcomes for Australa-
sians with FH has driven the establishment of an Australian
and New Zealand Registry for Familial Hypercholesterolaemia
(ANZRFH). The ANZRFH is intended to provide supporting
infrastructure in four key areas: (i) address a current gap in the
flow of data for measuring the quality of healthcare; (ii)
support basic research through provision of high-quality,
de-identified aggregate data; (iii) enable geographically equi-
table access to clinical trials; and (iv) promulgate information
about best practice and care services, particularly as we enter
the era of precision medicine.
In contrast to registries intended primarily for descriptive
or social networking purposes, the ANZRFH design requires
a high level of rigour to effectively address focused and
specific analytical questions. The registry aims are the
primary consideration for designing data collection, data
elements, natural history studies, data security, organisation
and governance, custodianship, ethics and privacy policy,
information output and resource and funding.
Data for the ANZRFH will be collected across multiple sites,
mostly from specialist lipid clinics and from laboratories that
report genetic results. Innovations in web-based platforms
allow for the ANZRFH to be highly interactive and accessible
in geographically disparate locations, with multiple-level,
private access for a range of user groups. Additional sites may
be added to the registry to increase the coverage of the FH
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population, with user groups being assigned appropriate
upload and access privileges. In this way, large general prac-
tice clinics with the local resources to upload and maintain the
currency of their patient data may also participate in the
Registry, irrespective of their geographical location. Given
that each general practitioner (GP) on average will see no
more than one or two cases of FH per year, GP entries will be
exceptional and the ANZRFH will be centrally coordinated, in
a manner consistent with approaches to cascade screening.
The choice of the minimum common data collection for
the ANZRFH has been guided by clinical and laboratory
experts, validity of data and a focus on identifying key indi-
cators of quality of care. Table 1 provides a list of the
common data items identified for inclusion in the ANZRFH.
Engagement with other registries and clinical groups, both
within Australia and globally, continues to be a key to ensur-
ing harmonisation of the data elements and the pathways
for their collection. The registry framework16 allows suitable
customisation for modifying of these elements or addition of
new data modules.
The ANZRFH enables different user groups, such as clini-
cal and genetic service providers, to have their own secure
access to the same system, irrespective of site location.
User access is controlled by a password and can be tailored
to allow specific and targeted rights to be assigned to indi-
viduals or groups. Access to extracts of de-identified aggre-
gate data by research investigators or any other third party,
including other registries, will be controlled through the
advisory board, human research ethics committees and the
data custodian, as illustrated in Figure 1.
The organisation and governance of the ANZRFH are
being developed to meet the Australian government and
Table 1 Common data set identified for inclusion in the ANZRFH
Identifying elements Clinical elements Genetic elements
Family name Age at diagnosis of FH Mutations in LDL-Receptor gene
Given names Index or relative Mutations in familial defective
Apolipoprotein B-100
DOB Height – optional Mutations in PCSK9




Postcode Family history of hypercholesterolaemia
Home phone Family history of premature CVD (men < 55, women < 60)
Mobile Personal history of premature CVD (men < 55, women < 60)
Email
Tendinous xanthomata
Next of kin family name Arcus cornealis prior to age 45 years
Next of kin given names
Next of kin address Highest pre-treatment
Next of kin state Cholesterol concentration (mmol/L)
Next of kin postcode LDL-cholesterol concentration (mmol/L)
Next of kin home phone Triglyceride concentration (mmol/L) – optional
Next of kin mobile HDL-cholesterol concentration (mmol/L) – optional
Next of kin email Lp(a) concentration (nmol/L) – optional
List of clinical providers and
their relationship to registrant
Is patient on medication now?
Index or relative On treatment
Relationship to index Cholesterol concentration (mmol/L
Degree of relation LDL-cholesterol concentration (mmol/L)
Triglyceride concentration (mmol/L) – optional
HDL-cholesterol concentration (mmol/L) – optional
Lp(a) concentration (nmol/L) – optional
Other CVD risk factors
Smoking
Hypertension
Systolic blood pressure – optional
Lp(a) concentration (nmol/L) – optional
Diastolic blood pressure – optional
Diabetes
Blood glucose concentration (mmol/L) – optional
Dutch Lipid Clinic Network Criteria Score
FH diagnostic categories
ANZRFH, Australian and New Zealand Registry for Familial Hypercholesterolaemia; BMI, body mass index; CVD, cardiovascular disease; DOB, date of birth; FH,
familial hypercholesterolaemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9.
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international standards for data collection. Specifically, an
Advisory Board, comprised of representatives of the FH clini-
cal networks, patient advocacy and laboratory experts, has
been convened.
Ethics
While the ANZRFH meets the standards and intent of a
quality registry,25 it will also provide de-identified data and
the opportunity for patients to volunteer for clinical trials.
Registrants may also elect to receive information about
advances in best practice and care services. For these
reasons, a voluntary recruitment process, which seeks
informed and prospective permission for the aforemen-
tioned options for participation, along with a description of
the potential benefits and risks of signing up to these
options, is being developed26 and will explicitly include the
opportunity to collect genotyping data. Subsequent audit of
recruitment will be included in the annual reports and will
reveal the level of success of this approach and whether
registrants elect to provide selective consent, for example,
give permission to collect and use genotyping data and be
contacted about advances in treatments, but not give per-
mission about eligibility for clinical trials.
Information outputs
The ANZRFH will extract longitudinal clinical data intended
to inform our understanding of the unmet needs in the care
of FH. Accordingly, the ANZRFH will report on the long-term
effects of treatments on patient outcomes that cannot be
gauged from shorter duration clinical trials. The data will
inform regional prevalence of FH, and will be used to
measure the effectiveness of cascade screening. Further-
more, the ANZRFH will help develop precision medicine by
providing an easy overview of the genetic variants associated
with the manifestation of disease. Specifically, the genetic
data can be used to identify eligibility for clinical trials for all
classes of therapeutic drugs launched against molecular
targets. The identity of potential volunteers will be commu-
nicated to the treating clinician for discussions with the
registrant and their family. Only the clinicians from the
ANZRFH will have access to the registrant.
Resources/funds
The potential resources and funds of existing registries are
variable. Some disease registries are developed by specific
research groups to serve a narrow research purpose, and are
reliant on the resources and funds of the research centres for
sustainability. Other registries may be developed and sup-
ported by patient advocacy groups, whereas others are
owned and funded by the pharmaceutical industry. In Aus-
tralia, clinical quality registries recognised as providing high-
priority comparative clinical performance data may receive
government funding through the Australian Commission on
Safety and Quality in Healthcare. The ANZRFH is being
developed collaboratively by partners across government,
clinical networks and patient advocacy groups. There are no
costs to registrants and there are no restrictions on the
ANZRFH seeking additional funding to support all or parts of
the stated aims. Sustainability is vital to ensuring that the
ANZRFH achieves cumulative successes: potential sources of
funding that have so far been identified include those arising
from partnership enterprises across public, private and
industry sectors.
Registry evaluation
The Australian Commission on Safety and Quality in Health-
care provides operating principles and technical standards
for Australian Clinical Quality Registries. The purpose of
these guidelines is to enhance the value of information from
existing registries, assist establishment and maintenance of
registries for measuring quality and suggest a best practice
model for registries. The ANZRFH is designed to meet all of
these operating principles and recommendations. The most
accurate measure of success for any registry would be the
degree to which that registry delivers on its stated objec-
tives. The goals of the ANZRFH are summarised in Table 2,
together with a proposed set of key performance indicators.
It is notable that, in an era of website hits and social media
such as Twitter, the circulation of information by and about
the Registry may be amplified and measured. A responsibility
of the Advisory Board will be to review these indicators and
provide commentary on the performance in the ANZRFH.
The success of the ANZRFH in fulfilling its goals should be
reported annually. The Advisory Board plays an important








Human research ethics committee
vTrials feasibility; Notification of eligibility to volunteer
vReporting on healthcare system
vDe-identified aggregate data
vPromulgate information about advances in best practice
Customised permissions allow on-








Figure 1 Structures and functions of the Australian and New
Zealand Registry for Familial Hypercholesterolaemia (ANZRFH).
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thereby ensuring its success. Investments in other registries
have been demonstrated to be cost-effective for the health
services.27,28 Accordingly, several expert groups, including
the American Heart Association, have called for the expan-
sion of their clinical registry programmes.29
Current and future trends in registries
To date, there are few national FH registries in only a few
European countries, such as The Netherlands, Spain and the
United Kingdom. Other national registries will soon be
operational such as the United States and Canada. However,
there are no global FH registries and inter-operability
between existing FH registries remains challenging. Software
packages are commercially available for clinical manage-
ment and cascade screening, and some patient registries
have been established. However, these efforts are frag-
mented and inaccessible to many FH stakeholders. Key areas
for the effective implementation of a value-based approach
to healthcare are clinician engagement, national infrastruc-
ture, high-quality data and outcome-based incentives.28
More should be done across all of these areas to coordinate
and harmonise the collection and use of evidence on FH.
The impact of any registry is enhanced through strong
networking between research centres, clinical services, other
registries and health data systems. For example, the ANZRFH
could provide de-identified aggregate data to the Australian
National Genetic Heart Disease Registry.30 A federated style
of registry development, which allows for optimal interac-
tion across different registries, is being undertaken by the
RD-CONNECT consortium (http://www.rd-connect.eu/).
This international consortium is combining resources to con-
struct a web-based platform that will enable networking
with multiple rare disease registries through exchange of
information contained in common data elements, common
use of unique patient identifiers, harmonised ethical frame-
works and patient consent forms, links with biobanks, and
research that includes clinical trials. One of the enabling
features of the RD-CONNECT registry platform is the use of
open-source web-based solutions for enabling greater inter-
operability between data collections. In this respect, the use
of open-source technology to build the ANZRFH embraces
the growing paradigm shift away from using commercial,
proprietary-protected software. The ANZRFH will be fully
inter-operable with RD-CONNECT.
The advisory board of the ANZRFH is now actively seeking
additional partners to further explore the opportunities to
harmonise and combine efforts that enhance the care of FH.
Ongoing engagement with other FH-specific registries, local
support groups, the International FH Foundations, the FH
Foundation USA, clinical networks and healthcare providers
has been very promising.
Conclusions
FH registries are being designed to coordinate the collec-
tion of evidence for enhancing healthcare, including
improving diagnostics and therapeutics. The success of reg-
istries in achieving these goals is influenced by their inter-
operability with other registries and their connectivity with
clinical networks, healthcare services, researchers, patient
advocacy groups and other data repositories. Converging
technologies and innovations in bioinformatics, targeted
policy directives and improved clinical networking in FH are
combining to create the necessary conditions for the estab-
lishment of such high-impact registries. The development
of the ANZFHR is only one example, among several, of FH
registries under construction around the world. If a global
network of interoperable, interconnected national registries
for FH is achieved, it promises to significantly contribute
towards the evidence-based enhancement in the worldwide
care of FH.
Table 2 Performance Indicators for ANZRFH
Registry aim Performance indicator
Nationwide impact and coordination • # contributing sites/national coverage
• # registrants and recruitment rates
• # inter-operability with other registries
Facilitate identification and recruitment of eligible volunteers
for participation in clinical trials.
• # participants in clinical trials
• # enquiries by industry
Facilitate service planning by analyses and reporting of data
collected by the Registry on prevalence, geographical
distribution, genetic variants associated with disease, clinical
features, clinical management and patient outcomes.
• # publication of annual report
• # citations of annual report by healthcare services and
clinical networks
• # measurement and reporting of healthcare quality (subset
of indicators of clinical effectiveness and appropriateness)
and cost-effectiveness
Enable research by providing aggregate, de-identified data to
research entities.
• # enquiries for data access
• nature of enquiries for access to data
• # of peer-reviewed research publications based on and
acknowledging the registry
Generate new knowledge to inform best practice and
healthcare.
• circulation of information
# = number of ANZRFH, Australian and New Zealand Registry for Familial Hypercholesterolaemia.
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